Abstract:Abstract Characterization of a patient’s tumor microenvironment is fundamental to advancing translational strategies in immuno-oncology. Histopathological evaluation of tissue slides from patients can provide this invaluable information, informing disease heterogeneity, tumor contexture, and target expression - all important to identifying patients more likely to benefit from therapy. However, availability of sufficient tissue is often a challenge to produce such a comprehensive tumor characterization. Measurement of target expression using an H&E slide could greatly reduce the usage of tissue for IHC making sections available for other investigative purposes. Here, an AI-driven predictive model was developed on H&E digital slides to simulate the expression of a tumor specific biomarker and CD3 across 4 different tumor types. Four epithelial tumor types (TNBC, NSCLC, ovarian, and cervical cancer) consisted of 400 H&E slides, 400 CD3 slides and 400 tumor specific biomarker IHC slides (100 cases per tumor) were used for this study. The Bio-AI Predict-X platform was utilized for the optimization of separate tumor models using pathology annotations as basis for development. The network output included tumor tiles as well as the tiles from adjacent stromal/normal tissue. Models were optimized until an AUC > 0.8 was achieved and prediction results were approved by the combined pathology teams. Predict-X was used for IHC marker quantification on a tile basis for both CD3 and the tumor specific biomarker slides with significant correlation to manual counts (p<0.001, r>0.8). Images from each case were co-registered so that ground truth for each tile with the IHC count was used in the predictive model. Tiles from tumor and corresponding adjacent stroma/normal tissue from all cases were subdivided into 3 groups for predictive model development. A training, validation, and test set were used, the latter of which was not used for development, only as a final assessment of model performance. A pan-tumor predictive model was developed for CD3 IHC on TNBC, cervical and ovarian cancers. The test set AUC values on cases from all 4 tumors were >0.7. Since the tumor specific biomarker stain was specific to tumor morphology, 4 separate predictive models were developed - one for each of the indications used with a test AUC >0.86. These findings suggest that deep learning can be used as a complementary method to prescreen H&E-stained images to enhance the detection rate of the tumor specific biomarker and CD3 positivity in patient tumors. Additional work will involve the optimization of these models for implementation in a clinical setting. Citation Format: Alan Jerusalmi, Krishna Bairavi, Ayushi Shah, Tom Chittenden, Mike Bonham, Chung-Wein Lee, Brandon Higgs, Anantharaman Muthuswamy. Development of predictive models for expression of a tumor specific biomarker and CD3 on H&E digital slides [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2):Abstract nr B092.

AI-based morphologic model for prediction of individual patient response to immune checkpoint inhibitors for bladder cancer.

Artificial Intelligence Meets Whole Slide Images: Deep Learning Model Shapes an Immune-Hot Tumor and Guides Precision Therapy in Bladder Cancer

Artificial intelligence algorithm developed to predict immune checkpoint inhibitors efficacy in non–small-cell lung cancer.

Abstract 4170: Artificial intelligence (AI)-based multi-modal approach using H&E and CT image for predicting treatment response of immune checkpoint inhibitor (ICI) in non-small cell lung cancer (NSCLC)

Abstract 5436: Developing artificial intelligence algorithms to predict response to neoadjuvant chemotherapy in HER2-positive breast cancer

Predicting immunotherapy response in advanced bladder cancer: a meta-analysis of six independent cohorts

Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma

Immunotherapy Efficacy Prediction in Cancer: An Artificial Intelligence Approach with Unannotated H&E Whole-Slide Images

Gene expression-based machine learning approach to predict immunotherapy response and survival in patients with advanced cancer.

Application of artificial intelligence (AI) features of nuclear morphology from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with MIBC undergoing cystectomy.

Development of a Molecular-Subtype-Associated Immune Prognostic Signature That Can Be Recognized by MRI Radiomics Features in Bladder Cancer.

Correlation of artificial intelligence (AI)-based spatial characteristics of tumor-infiltrating lymphocytes outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial cancer (mUC).

A digital pathology AI model to predict immune-oncology biomarker status and pembrolizumab response in a real-world cohort of patients with colorectal and breast cancer.

Abstract 5182: Exploiting tumor RNA-sequencing data for prediction of immune checkpoint inhibition response

Evaluation of tumor response to immune checkpoint inhibitors by a 3D immunotumoroid model

Abstract B092: Development of predictive models for expression of a tumor specific biomarker and CD3 on H&E digital slides

Multimodal machine learning model prediction of “individual” response to immunotherapy in 1L stage IV NSCLC.

Abstract 4951: Integrative multi-omic machine learning model predicts neoadjuvant immunotherapy response using molecular data and deep learning-derived features from digital pathology

Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors

Predicting clinical outcomes in the S1314-COXEN trial using a multimodal deep learning model integrating histopathology, cell types, and gene expression.

Novel machine learning algorithm to predict response to immunotherapy in patients with small cell and non-small cell lung cancer.